AC Immune SA
No SEC Form 4 filings for $ACIU in the last 30 days.
See all $ACIU insider activity →AC Immune SA (ACIU) shares rose 3.9% premarket after reporting positive Phase 1 trial data for ACI-19764, an NLRP3 inhibitor. The drug was safe, well-tolerated, and showed brain penetration. Phase 1b results are expected by year-end, with full results in 2027. ACI-19764 targets chronic inflammation in various diseases.
AC Immune (ACIU) shares rose 3.4% pre-open after the FDA granted Fast Track status to its ACI-7104 anti-alpha-synuclein therapy and cleared its IND. The move allows Phase 2 VacSYn trial enrollment to expand to U.S. sites. Interim 76-week Part 1 data showed a favorable safety profile. The stock was near $2.37.
AC Immune SA (ACIU) said the FDA granted Fast Track designation to its ACI-7104 anti-alpha-synuclein immunotherapy for early Parkinson’s. The drug is in the VacSYn Phase 2 trial; Part 1 interim data at 76 weeks reported safety and a 100% immunogenicity responder rate. Next steps include U.S. site expansion after IND clearance and week-100 results in H2 2026.
Over the past 7 days, alphai's AI scored 1 news story mentioning ACIU (AC Immune SA). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ACIU coverage spans financial news, technology and regulation.
Positive safety and pharmacokinetic data may boost investor confidence and support near‑term price appreciation.
Regulatory acceleration plus interim safety data increases probability of near-term clinical progress and can extend the valuation runway for ACI-7104.
Fast Track status can accelerate development and regulatory interactions for ACI-7104, supporting a more favorable path toward later trial readouts.
Near-term clinical readouts and partner milestone receipts extend funding visibility, but the update is still a roadmap rather than a new efficacy datapoint.
Conference disclosures may influence near-term sentiment around ACIU’s neurodegeneration pipeline, but no new trial readout numbers are provided here.
alphai scores every news story that mentions ACIU with an AI model for sentiment and relevance, and aggregates insider trades from AC Immune SA's SEC EDGAR Form 4 filings. Figures refresh continuously.
AC Immune SA (ACIU) shares rose 3.9% premarket after reporting positive Phase 1 trial data for ACI-19764, an NLRP3 inhibitor. The drug was safe, well-tolerated, and showed brain penetration. Phase 1b results are expected by year-end, with full results in 2027. ACI-19764 targets chronic inflammation in various diseases.
2 min readAC Immune (ACIU) shares rose 3.4% pre-open after the FDA granted Fast Track status to its ACI-7104 anti-alpha-synuclein therapy and cleared its IND. The move allows Phase 2 VacSYn trial enrollment to expand to U.S. sites. Interim 76-week Part 1 data showed a favorable safety profile. The stock was near $2.37.
4 min readAC Immune SA (ACIU) said the FDA granted Fast Track designation to its ACI-7104 anti-alpha-synuclein immunotherapy for early Parkinson’s. The drug is in the VacSYn Phase 2 trial; Part 1 interim data at 76 weeks reported safety and a 100% immunogenicity responder rate. Next steps include U.S. site expansion after IND clearance and week-100 results in H2 2026.
4 min readAC Immune SA (NASDAQ: ACIU) reported a half-year update for June 30, 2026, highlighting Phase 2 VacSYn Part 1 full results for ACI-7104 in H2 2026, Phase 1/1b data for ACI-19764 in H2 2026, and Phase 1 PET results for ACI-19626. Cash was CHF 75.4m. Revenues were CHF 16.2m. A $12m Takeda milestone was triggered for ACI-24.
6 min readAC Immune SA (NASDAQ: ACIU) said it will present three neurodegenerative disease pipeline updates at AAIC 2026 in London (July 12–15). It plans to share early human imaging for the [18F]ACI-19626 TDP-43 PET tracer, Phase 1 data for NLRP3 inhibitor ACI-19764, and preclinical results for an alpha-synuclein aggregation inhibitor.
2 min readAC Immune SA (NASDAQ: ACIU) reported interim 12-month Phase 1b/2 ABATE trial data for ACI-24 in 74 prodromal Alzheimer’s patients across AD1–AD3 cohorts. Company said ACI-24 was generally safe and well tolerated with no ARIA-E and anti–Abeta antibodies detected at all dose levels with a dose response. AD4 is ongoing with an added adjuvant; Takeda has an option/license agreement.
4 min readAC Immune SA (NASDAQ: ACIU) said it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation to extend Part 1 of its Phase 2 VacSYn trial of ACI-7104 in early Parkinson’s disease by 2 years to assess long-term safety and efficacy. Final Part 1 results (to week 104) are expected in H2 2026.
4 min readAC Immune SA CEO Andrea Pfeifer sold 10,000 common shares in an open-market transaction on May 15, 2026, at a weighted average price of $2.7935 per share. Following this sale, Pfeifer directly holds 3,820,288 common shares, which includes 1,921,005 shares underlying restricted share units, and her spouse indirectly holds an additional 14,000 shares. This transaction was made under a 10b5-1 plan.
2 min readAC Immune SA's CEO, Andrea Pfeifer, has filed an initial statement of beneficial ownership, revealing her holdings in the company. She directly owns 3,840,288 Common Shares, which includes 1,921,005 Common Shares from restricted share units, and indirectly holds 14,000 Common Shares via her spouse. The filing also details fully vested share options with exercise prices between $2.03 and $9.53, expiring from 2027 to 2032.
2 min readAC Immune will host an industry symposium focused on a precision prevention approach to Parkinson's disease, drawing lessons from Alzheimer's. The company will also present preclinical data on its first-in-class TDP-43 PET-tracer, ACI-19626, at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2026). The symposium will cover various aspects of Parkinson's research, including alpha-synuclein targeting and interim results from the Phase 2 VacSYn trial of ACI-7104.056.
4 min read
